


## Midatech Pharma US Inc. (NASDAQ: DARA)

8601 Six Forks Road

Suite 160

Raleigh, NC 27615

Share Price	\$0.00	
Volume	0	
Shares Outstanding	19,755,595	
Market Cap	\$N/A	
52 Week High	\$1.05	
52 Week Low	\$0.67	
as of 11/21/2017		



## **Overview**

DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA has comprehensive commercial coverage across the national oncology market through a series of agreements with a number of specialty pharmacy providers, leading group purchasing organizations (GPOs), retail partners, reimbursement experts, and an industry-leading third-party logistics provider. As part of an integrated national network with annual sales of over \$1 billion in cancer therapeutics, DARA has significant commercial scale and capabilities. Its distribution network consists of more than 45,000 retail pharmacies, mail order pharmacies, and long-term care facilities. This provides DARA with established reimbursement and logistics expertise, as well as partnering opportunities with more than 300 sales and marketing personnel uniquely focused on oncology and oncology support products. This comprehensive network of partners is rare if not unique

among companies in the oncology supportive care area and provides DARA a strong foundation for product introductions into this underserved market.

# **Management Team**

David J. Drutz. MD

Executive Chairman and Chief Medical Officer

Christopher G. Clement

President and Chief Executive Officer

David L. Tousley

Executive Vice President and Chief Financial Officer

**David Benharris** 

Vice President Sales, Marketing and Business Development

Mary Kay Delmedico, PhD

Vice President Scientific & Regulatory Affairs

#### **Recent News**

Wednesday, December 02, 2015 - 04:30 PM

DARA BioSciences Announces Stockholder Approval of Merger With Midatech

Monday, November 02, 2015 - 04:30 PM

DARA BioSciences Announces Third Quarter 2015 Results

Tuesday, October 06, 2015 - 08:00 AM

DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015

Monday, October 05, 2015 - 08:00 AM

DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush

Wednesday, September 23, 2015 - 04:30 PM

DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015

### Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.